Newsworthy
FDA Approvals, News & UpdatesLung CancerNewsworthy
In November 2017, the FDA approved Alecensa for the treatment of all patients with metastatic non–small-cell lung cancer (NSCLC) and ALK mutation.
FDA Approvals, News & UpdatesLymphomaNewsworthy
In October 2017, the FDA accelerated the approval of Calquence for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy.
Breast CancerFDA Approvals, News & UpdatesNewsworthy
Read about Verzenio, which was approved by the FDA in 2017, in combination with fulvestrant, for treatment of women with HR-positive, HER2-positive, HER2-negative advanced, or metastatic breast cancer that progressed after endocrine therapy.
FDA Approvals, News & UpdatesGynecologic CancersNewsworthyOvarian Cancer
In August 2017, the FDA approved Lynparza tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a response to platinum-based chemotherapy.
Breast CancerFDA Approvals, News & UpdatesNewsworthy
On July 17, 2017, the FDA approved Nerlynx (neratinib; from Puma Biotechnology) for long-term adjuvant treatment of early-stage, HER2-positive breast cancer in patients who received previous therapy with Herceptin (trastuzumab).
